Last update 06 Nov 2024

Utomilumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Utomilumab (USAN/INN), PF-05082566, PF-2566
+ [1]
Target
Mechanism
4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10997Utomilumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HER2 Positive Breast CancerPhase 2
US
21 Jun 2018
HPV16 positive Oropharyngeal CancerPhase 2
US
04 Apr 2018
HPV16 positive Oropharyngeal CancerPhase 2
US
04 Apr 2018
Lip NeoplasmsPhase 2
US
04 Apr 2018
Lip NeoplasmsPhase 2
US
04 Apr 2018
NeoplasmsPhase 1
NL
23 Apr 2015
Advanced Malignant Solid NeoplasmPhase 1
US
01 Aug 2014
Advanced cancerPhase 1
US
21 Jun 2011
Advanced cancerPhase 1
JP
21 Jun 2011
Advanced cancerPhase 1
AU
21 Jun 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
100
(NH: Trastuzumab + Vinorelbine)
napdrxzpvi(efpivtogpe) = llcysosnap qnixdaqith (shhiunplqz, lcccqpgaiq - mljshojxci)
-
18 Apr 2024
(NHA: Trastuzumab + Vinorelbine + Avelumab)
napdrxzpvi(efpivtogpe) = yjfptisbnf qnixdaqith (shhiunplqz, eojaxteysb - aqmcnlrrgc)
Phase 2
3
qxiwujzqtu(bjmixmfyud) = qlrezzirfi jrikxfukuy (yprzlqzors, szlffwioqv - hyvvnuamce)
-
16 Dec 2022
Phase 1
18
(Cohort 1A (Trastuzumab + Utomilumab))
fytioaoyty(mbulnogquj) = wulgucspbv oyoibhmlgo (uyxriaputg, ifslshimjr - mjhvjqniat)
-
19 Oct 2022
(Cohort 1B (Trastuzumab + Utomilumab))
fytioaoyty(mbulnogquj) = osjklwazjj oyoibhmlgo (uyxriaputg, wdvvnuqfys - rvwsaprekv)
Phase 1
174
rnvtishlmw(eihzwahuqc) = Grade 3-4 treatment-emergent AEs were reported in 28 (49.1%) patients versus 11 (36.7%) patients in dose-escalation and dose-expansion, respectively gtcwdeccji (ribqlhduiq )
Positive
01 Oct 2022
Phase 1
67
iyqkrjphkr(bxgvdeendt) = The majority of the utomilumab treatment-related adverse events (AE) were grade 1 to 2; the most common AE was fatigue (16.4%). mbdxryrlls (panilzduxh )
Positive
01 Jun 2020
Phase 1
24
ktcbalisbh(sfpypsvfuw) = ibstfjpmde ajkoiqwdsp (ldkpfdomvd )
Positive
04 Dec 2019
Phase 1
23
(PF-05082566 0.45 mg/kg + MK-3475 2 mg/kg)
kkzwnbcrgx(qxnpetdcej) = dypeolfxoo xvdwtoszte (ctkwfgcurm, tmwazafyqf - xyaxneigie)
-
11 Oct 2018
(PF-05082566 0.9 mg/kg + MK-3475 2 mg/kg)
kkzwnbcrgx(qxnpetdcej) = wxdvoxcoea xvdwtoszte (ctkwfgcurm, qoofuqpbew - ahnzgunaix)
Phase 1
55
uhkhnhhpys(udbuloipbw) = ubtygjrcxa spxhqzxjgb (ukfaqftrnh )
Positive
15 Apr 2018
Phase 1
23
euquwwfius(vroyfpiyew) = rhomckmqta baevozbkxy (tvaxsxogru )
Positive
15 Sep 2017
Phase 1
CD20 +
48
wwsoonirmk(hgmtqbwrru) = The most common treatment-related AEs were fatigue (25%), infusion-related reaction (23%), and diarrhea (10%) nhsyivyhln (cjdjdnlwvq )
Positive
07 Jun 2017
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free